LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized Trial

Patients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex interplay of chronic inflammation and traditional cardiometabolic risk factors. A newly published study explores the relationship between hepatic steatosis (also known as fatty liver disease) and cardiovascular risk in people living with RA. Published as a post-hoc analysis of the FRANCIS randomized trial, the research includes Manuel Castro Cabezas, Scientific Officer at P95 Julius Clinical, among the contributing authors, underscoring the organization’s continued commitment to advancing research at the intersection of metabolic, cardiovascular, and inflammatory diseases.

Read the full study →

This analysis draws on data from the FRANCIS randomized trial to further examine the connections between liver health, cardiometabolic risk, and cardiovascular outcomes in individuals with rheumatoid arthritis. As researchers continue to investigate the factors that contribute to increased cardiovascular risk in RA, studies like this help deepen our understanding of how metabolic and inflammatory conditions intersect.

The research adds to an evolving body of evidence focused on improving cardiovascular risk assessment and management in patients with chronic inflammatory diseases. The involvement of Manuel Castro Cabezas reflects P95 Julius Clinical’s ongoing commitment to supporting innovative research that advances knowledge in cardiometabolic and inflammatory health.